Erschienen in:
01.11.2017 | Case report
Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings
verfasst von:
Ai Uchida, Maho Watanabe, Aya Nawata, Yosuke Ikari, Masaru Sasaki, Kana Shigemoto, Satoshi Hisano, Hitoshi Nakashima
Erschienen in:
CEN Case Reports
|
Ausgabe 2/2017
Einloggen, um Zugang zu erhalten
Abstract
Immune-checkpoint inhibitor nivolumab (anti-PD-1 antibody) blocks T cell inhibition and stimulate immunologic response toward cancer cells. It was also revealed that PD-1/PD-L1 interaction crucially controls the effector differentiation of auto-reactive T cells to maintain self-tolerance. Therefore, potential autoimmunological side-effect can occur in any organ. Here, we report a case of 67-year-old Japanese male with lung adenocarcinoma treated with nivolumab who developed acute tubulointerstitial nephritis after the third infusion of nivolumab. Kidney biopsy showed distinct histological findings: Proliferation of CD38 positive and IgG positive plasma cells, and affluent infiltration of FoxP3+ regulatory T cells. Herein, we do pathological discussion concerning acute tubulointerstitial nephritis occurred in this case based on these histological findings.